Home Newsfeeds Morgan Stanley Maintains Overweight on Treace Medical Concepts, Raises Price Target to $28

Morgan Stanley Maintains Overweight on Treace Medical Concepts, Raises Price Target to $28

Morgan Stanley analyst Drew Ranieri maintains Treace Medical Concepts (NASDAQ:TMCI) with a Overweight and raises the price target from $23 to $28.

byBenzinga Newsdesk

October 11, 2022

1 minute read

Morgan Stanley analyst Drew Ranieri maintains Treace Medical Concepts (NASDAQ:TMCI) with a Overweight and raises the price target from $23 to $28.

Citigroup Maintains Neutral on WalkMe, Raises Price Target to $12

By Benzinga Newsdesk

February 17, 11:39 AM

Citigroup analyst Tyler Radke maintains WalkMe (NASDAQ:WKME) with a Neutral and raises the price target from $11 to $12.

WKME

Goldman Sachs Maintains Sell on EverCommerce, Lowers Price Target to $7

By Benzinga Newsdesk

November 14, 10:31 AM

Goldman Sachs analyst Gabriela Borges maintains EverCommerce (NASDAQ:EVCM) with a Sell and lowers the price target from $8 to $7.

EVCM

Lantern Bolsters Board With Columbia Care VP, Verano Taps M&A Pro, And Other Key Exec Moves

By Jelena Martinovic

August 31, 9:18 AM

Top CEOs, investors and leaders in the cannabis industry will soon convene at the Benzinga Cannabis Capital Conference on Sept. 13-14 in Chicago.

CCHWF

Jim Cramer Sees Eli Lilly As More Than A ‘One-Trick Pony’ After FDA Advisors Back Its Alzheimer’s Drug: ‘It’s Ultimately Headed To A Trillion Dollar Valuation’

By Benzinga Neuro

June 11, 11:52 PM

Jim Cramer has expressed his confidence in Eli Lilly and Co, citing the company's diverse drug portfolio and the recent endorsement of its Alzheimer's treatment by FDA advisors.

LLY

Morgan Stanley Maintains Overweight on Treace Medical Concepts, Raises Price Target to $28

Related Posts

Citigroup Maintains Neutral on WalkMe, Raises Price Target to $12

Goldman Sachs Maintains Sell on EverCommerce, Lowers Price Target to $7

Lantern Bolsters Board With Columbia Care VP, Verano Taps M&A Pro, And Other Key Exec Moves

Jim Cramer Sees Eli Lilly As More Than A ‘One-Trick Pony’ After FDA Advisors Back Its Alzheimer’s Drug: ‘It’s Ultimately Headed To A Trillion Dollar Valuation’